FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and immunology. Described are new antibodies or antigen-binding fragments, which specifically bind to siglec-15. In some embodiments, antigen-binding fragments may block biological activity of siglec-15 and are useful in composition for treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of siglec-15, such as conditions where there is an increase in bone degradative activity of osteoclasts. Invention also relates to cells expressing antibodies or antigen-binding fragments such as monoclonal, humanised or chimeric antibodies.
EFFECT: additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using antibodies and fragments are also disclosed.
26 cl, 20 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR TUMOURS VOLUME REDUCTION | 2010 |
|
RU2627163C2 |
| PEPTIDES-DERIVATIVES IL-4 FOR MODULATION OF CHRONIC INFLAMMATORY RESPONSE AND TREATMENT OF AUTOIMMUNE DISEASES | 2009 |
|
RU2542375C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
